SynthesisMedicine2019
Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis.
Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic value of absolute lymphocyte count and neutrophil-to-lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Pooled it
- Development and multicenter validation of an immunoinflammatory marker-MRI model for pathological complete response after neoadjuvant chemotherapy in invasive breast cancer.Translational cancer research · 2026Article
- HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer-A Multicenter Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Is the Neutrophil-to-Lymphocyte Ratio a Predictive Factor of Pathological Complete Response in Egyptian Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?Medicina (Kaunas, Lithuania) · 2025Article
- The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.Scientific reports · 2024Article
- Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.Journal of cancer research and clinical oncology · 2023Article
- Review
- Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography.World journal of clinical cases · 2022Article
- A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Disease markers · 2022Article
- Article
- Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients.Scientific reports · 2021Article
- Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer.Frontiers in oncology · 2021Article
- Article
- Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?World journal of surgical oncology · 2020Article
- Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review.Cancers · 2020Review
- Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.BioMed research international · 2020Article
- The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer.OncoTargets and therapy · 2020Review
- Cell Ratio Differences in Peripheral Blood between Early- and Late-Onset Parkinson's Disease: A Case-Control Study.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to evaluate the correlation of neutrophil-to-lymphocyte ratio (NLR) with pathological response, disease-free survival (DFS), and overall survival (OS) in patients with breast cancer and under neoadjuvant chemotherapy (NAC). MATERIALS AND
methodsWe performed a systematical search using Cochrane Library, ScienceDirect, PubMed, Embase, and Web of Science up to May 2018. On the basis of the data directly obtained from the available studies, the odds ratios (ORs) and their 95% confidence intervals (95% CIs) were pooled on the basis of higher or lower NLR levels.
resultsThe meta-analysis showed that high NLR was significantly associated with poor NAC response (OR = 2.27, 95% CI: 1.46-3.53, P < .001) but not with the DFS (OR = 1.18, 95% CI: 0.78-1.78, P = .435) and OS (OR = 2.781, 95% CI: 0.54-14.32, P = .221).
conclusionAlthough high NLR was significantly associated with poor pathological response, we were unable to demonstrate the prognostic value of NLR for DFS and OS in patients with breast cancer who were undergoing NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.